HPV-positive oropharyngeal cancer

Human papillomavirus-positive oropharyngeal cancer
Other namesHPV16+ oropharyngeal cancer, HPV16+OPC
Image of human papilloma virus associated oropharyngeal cancer, under a microscope. The tissue has been stained to show the presence of the virus by in situ hybridisation
Microscope image of tumour showing HPV positivity by in situ hybridization
SpecialtyOncology 
Edit this on Wikidata
SymptomsSore or blister in back of mouth, difficulty with speech, swallowing or breathing, swelling in neck, loss of appetite, loss of weight, and weakness
CausesHuman papilloma virus
Risk factorsoral sexual contact
Diagnostic methodEndoscopy, Biopsy, Staining for p16, CT Scan,
Differential diagnosisTobacco associated oropharyngeal cancer
PreventionVaccination
TreatmentSurgery, radiation, chemotherapy
Frequency22,000 cases globally (2008)[1][2]

Human papillomavirus-positive oropharyngeal cancer (HPV-positive OPC or HPV+OPC), is a cancer (squamous cell carcinoma) of the throat caused by the human papillomavirus type 16 virus (HPV16). In the past, cancer of the oropharynx (throat) was associated with the use of alcohol or tobacco or both, but the majority of cases are now associated with the HPV virus, acquired by having oral contact with the genitals (oral-genital sex) of a person who has a genital HPV infection. Risk factors include having a large number of sexual partners, a history of oral-genital sex or anal–oral sex, having a female partner with a history of either an abnormal Pap smear or cervical dysplasia, having chronic periodontitis, and, among men, younger age at first intercourse and a history of genital warts. HPV-positive OPC is considered a separate disease from HPV-negative oropharyngeal cancer (also called HPV negative-OPC and HPV-OPC).

HPV-positive OPC presents in one of four ways: as an asymptomatic abnormality in the mouth found by the patient or a health professional such as a dentist; with local symptoms such as pain or infection at the site of the tumor; with difficulties of speech, swallowing, and/or breathing; or as a swelling in the neck if the cancer has spread to local lymph nodes. Detection of a tumour suppressor protein, known as p16, is commonly used to diagnose an HPV associated OPC. The extent of disease is described in the standard cancer staging system, using the AJCC TNM system, based on the T stage (size and extent of tumor), N stage (extent of involvement of regional lymph nodes) and M stage (whether there is spread of the disease outside the region or not), and combined into an overall stage from I–IV. In 2016, a separate staging system was developed for HPV+OPC, distinct from HPV-OPC.

Whereas most head and neck cancers have been declining as reduced smoking rates have declined, HPV-positive OPC has been increasing. Compared to HPV-OPC patients, HPV-positive patients tend to be younger, have a higher socioeconomic status and are less likely to smoke. In addition, they tend to have smaller tumours, but are more likely to have involvement of the cervical lymph nodes. In the United States and other countries, the number of cases of oropharyngeal cancer has been increasing steadily, with the incidence of HPV-positive OPC increasing faster than the decline in HPV-negative OPC. The increase is seen particularly in young men in developed countries, and HPV-positive OPC now accounts for the majority of all OPC cases. Efforts are being made to reduce the incidence of HPV-positive OPC by introducing vaccination that includes HPV types 16 and 18, found in 95% of these cancers, prior to exposure to the virus. Early data suggest a reduction in infection rates.

In the past, the treatment of OPC was radical surgery, with an approach through the neck and splitting of the jaw bone, which resulted in morbidity and poor survival rates. Later, radiotherapy with or without the addition of chemotherapy, provided a less disfiguring alternative, but with comparable poor outcomes. Now, newer minimally invasive surgical techniques through the mouth have improved outcomes; in high risk cases, this surgery is often followed by radiation and/or chemotherapy. In the absence of high quality evidence regarding which treatment provides the best outcomes, management decisions are often based on one or more of the following: technical factors, likely functional loss, and patient preference. The presence of HPV in the tumour is associated with a better response to treatment and a better outcome, independent of the treatment methods used, and a nearly 60% reduced risk of dying from the cancer. Most recurrence occurs locally and within the first year after treatment. The use of tobacco decreases the chances of survival.

Signs and symptoms

HPV+OPC presents in one of four ways: as an asymptomatic abnormality in the mouth found by the patient or a health professional such as a dentist; with local symptoms such as pain or infection at the site of the tumor; with difficulties of speech, swallowing, and/or breathing; or as a swelling in the neck (if the cancer has spread to lymph nodes). These may be accompanied by more general symptoms such as loss of appetite, weight loss, and weakness.[3]

Cause

Electron micrograph of Human Papilloma Viruses

Most mucosal squamous cell head and neck cancers, including oropharyngeal cancer (OPC), have historically been attributed to tobacco and alcohol use. However this pattern has changed considerably since the 1980s. It was realised that some cancers occur in the absence of these risk factors and an association between human papilloma virus (HPV) and various squamous cell cancers, including OPC, was first described in 1983.[4][5] Since then both molecular and epidemiological evidence has been accumulating, with the International Agency for Research on Cancer (IARC) stating that high-risk HPV types 16 and 18 are carcinogenic in humans, in 1995,[6] and In 2007 that HPV was a cause for oral cancers.[7][8] Human papillomavirus (HPV)-positive cancer (HPV+OPC) incidence has been increasing while HPV-negative (HPV-OPC) cancer incidence is declining, a trend that is estimated to increase further in coming years.[9] Since there are marked differences in clinical presentation and treatment relative to HPV status, HPV+OPC is now viewed as a distinct biologic and clinical condition.[10][11][12]

Human HPV has long been implicated in the pathogenesis of several anogenital cancers including those of the anus, vulva, vagina, cervix, and penis.[13] In 2007 it was also implicated by both molecular and epidemiological evidence in cancers arising outside of the anogenital tract, namely oral cancers. HPV infection is common among healthy individuals, and is acquired through oral sex. Although less data is available, prevalence of HPV infection is at least as common among men as among women, with 2004 estimates of about 27% among US women aged 14–59.[8]

HPV oral infection precedes the development of HPV+OPC.[8][5] Slight injuries in the mucous membrane serve as an entry gate for HPV, which thus works into the basal layer of the epithelium.[14][15] People testing positive for HPV type 16 virus (HPV16) oral infection have a 14 times increased risk of developing HPV+OPC.[14] Immunosuppression seems to be an increased risk factor for HPV+OPC.[5] Individuals with TGF-β1 genetic variations, specially T869C, are more likely to have HPV16+OPC.[16] TGF-β1 plays an important role in controlling the immune system. In 1993 it was noted that patients with human papillomavirus (HPV)-associated anogenital cancers had a 4-fold increased risk of tonsillar squamous-cell carcinoma.[17] Although evidence suggests that HPV16 is the main cause of OPC in humans not exposed to smoking and alcohol, the degree to which tobacco and/or alcohol use may contribute to increase the risk of HPV+OPC has not always been clear[5] but it appears that both smoking and HPV infection are independent and additive risk factors for developing OPC.[18] The connection between HPV-infection and oropharyngeal cancer is stronger in regions of lymphoepithelial tissue (base of tongue and palatine tonsils) than in regions of stratified squamous epithelium (soft palate and uvula).[19] Human herpesvirus-8 infection can potentiate the effects of HPV-16.[20]

Risk factors

Risk factors include a high number of sexual partners (25% increase >= 6 partners), a history of oral-genital sex (125% >= 4 partners), or anal–oral sex, a female partner with a history of either an abnormal Pap smear or cervical dysplasia,[21] chronic periodontitis,[22][23] and, among men, decreasing age at first intercourse and history of genital warts.[24][25][26][27]

Pathology

Appearance of basaloid pattern of squamous cell cancer under the microscope
Basaloid pattern of squamous cell cancer

Cancers of the oropharynx primarily arise in lingual and palatine tonsil lymphoid tissue that is lined by respiratory squamous mucosal epithelium, which may be invaginated within the lymphoid tissue. Therefore, the tumour first arises in hidden crypts. OPC is graded on the basis of the degree of squamous and keratin differentiation into well, moderate or poorly (high) differentiated grades. Other pathological features include the presence of finger-like invasion, perineural invasion, depth of invasion and distance of the tumour from resection margins. Phenotypic variants include basaloid squamous carcinoma, a high grade form (see Chung Fig. 35-3(C)[28] and illustration here). They are most commonly non-keratinising. HPV+OPC also differs from HPV-OPC in being focal rather than multifocal and not being associated with pre-malignant dysplasia. HPV+OPC patients are therefore at less risk of developing other malignancies in the head and neck region, unlike other head and neck primary tumours that may have associated second neoplasms, that may occur at the same time (synchronous) or a distant time (metachronous), both within the head and neck region or more distantly. This suggests that the oncogenic alterations produced by the virus are spatially limited rather than related to a field defect.[29][28][30]

Anatomy

Anatomy of oropharynx and surrounding structures

The oropharynx, at the back of the mouth, forms a circle and includes the base of the tongue (posterior third) below, the tonsils on each side, and the soft palate above, together with the walls of the pharynx, including the anterior epiglottis, epiglottic valleculae and branchial cleft at its base. The oropharynx is one of three divisions of the interior of the pharynx based on their relation to adjacent structures (nasal pharynx (nasopharynx), oral pharynx (oropharynx) and laryngeal pharynx (laryngopharynx - also referred to as the hypopharynx), from top to bottom). The pharynx is a semicircular fibromuscular tube joining the nasal cavities above to the larynx (voice box) and oesophagus (gullet), below, where the larynx is situated in front of the oesophagus.[31]

The oropharynx lies between the mouth (oral cavity) to the front, and the laryngopharynx below, which separates it from the larynx. The upper limit of the oropharynx is marked by the soft palate, and its lower limit by the epiglottis and root of the tongue. The oropharynx communicates with the mouth, in front through what is known as the oropharyngeal isthmus, or isthmus of the fauces. The isthmus (i.e. connection) is formed above by the soft palate, below by the posterior third of the tongue, and at the sides by the palatoglossal arches. The posterior third of the tongue, or tongue base contains numerous follicles of lymphatic tissue that form the lingual tonsils. Adjacent to the tongue base, the lingual surface of the epiglottis, which curves forward, is attached to the tongue by median and lateral glossoepiglottic folds. The folds form small troughs known as the epiglottic valleculae. The lateral walls are marked by two vertical pillars on each side, the pillars of the fauces, or palatoglossal arches. More properly they are separately named the palatoglossal arch anteriorly and the palatopharyngeal arch posteriorly. The anterior arch is named from the palatoglossal muscle within, running from the soft palate to the tongue (glossus), while the posterior arch similarly contains the palatopharyngeal muscle running from the soft palate to the lateral pharynx. Between the arches lies a triangular space, the tonsillar fossa in which lies the palatine tonsil, another lymphoid organ. [32]

The external pharyngeal walls consisting of the four constrictor muscles form part of the mechanism of swallowing. The microscopic anatomy is composed of four layers, being from the lumen outwards, the mucosa, submucosa, muscles and the fibrosa, or fibrous layer. The mucosa consists of stratified squamous epithelium, that is generally non-keratinised, except when exposed to chronic irritants such as tobacco smoke. The submucosa contains aggregates of lymphoid tissue.[32][33]

Patterns of spread

Cancers arising in the tonsillar fossa spread to the cervical lymph nodes, primarily the subdigastric (upper jugular) lymph nodes (level II), with secondary involvement of the mid (level III) and low (level IV) jugular nodes and sometimes the posterior cervical nodes (level V). Base of tongue cancers spread to the subdigastric and mid jugular nodes, and occasionally posterior cervical nodes but being closer to the midline are more likely to have bilateral nodal disease. Tonsillar cancers rarely spread to the contralateral side unless involving the midline.[34]

Mechanism

diagram of the genome of human papillomavirus
Genomic structure of HPV

Virology

HPV associated cancers are caused by high-risk strains of HPV, mainly HPV-16 and HPV-18.[35] HPV is a small non-enveloped DNA virus of the papillomavirus family. Its genome encodes the early (E) oncoproteins E5, E6 and E7 and the late (L) capsid proteins L1 and L2. The virus gains access to the mucosa through microlesions, where it infects the basal layer of cells, which are still able to proliferate. While the virus does not replicate in these cells, expression of its early genes stimulates proliferation and lateral expansion of the basal cells. As this moves the virus particles into the overlying suprabasal layers, late viral gene expression occurs, enabling replication of the circular viral genome (see figure) and structural proteins. As these are pushed into the most superficial mucosal layers, complete viral particles are assembled and released.[36]

Oncogenesis

An increased risk of HPV+OPC is observed more than 15 years after HPV exposure,[8] pointing to a slow development of the disease, similar to that seen in cervical cancer. Relative to HPV-OPC, the oncogenic molecular progression of HPV+OPC is poorly understood.[28] The two main viral oncoproteins of the high risk HPV types are E6 and E7. These are consistently expressed in malignant cell lines, and if their expression is inhibited the malignant phenotype of the cancer cells is blocked. Either of these oncoproteins can immortalise cell lines,[37] but are more efficient when both are expressed, since their separate molecular roles are synergistic.[35][36] The E6 and E7 oncogenes become integrated into host-cell DNA, and the oncoproteins they express interfere with a variety of predominantly antiproliferative cellular regulatory mechanisms. They bind to and inactivate the best known of these mechanisms, the tumor suppressor proteins p53 and retinoblastoma protein pRB (pRb) leading to genomic instability and then cell cycle deregulation (see Chung et al., 2016 Fig. 35.2).[28] Further, yet to be elicited, mechanisms are required for the final steps of malignant transformation of HPV infected cells.[28]

HPV- and HPV+OPC are distinguishable at the molecular level. The naturally occurring (wild type) p53 is widely involved in cellular processes, including autophagy, response to DNA damage, cell cycle regulation and senescence, apoptosis and the generation of adenosine triphosphate (ATP) through oxidative phosphorylation.[38] The gene encoding p53 is inactivated by E6 at the protein level and is found as the wild type in HPV+OPC but mutated in HPV-OPC. In HPV+OPC p53 protein undergoes accelerated degradation by E6, drastically reducing its levels, while in HPV-OPC it undergoes genetic mutation, which may result in synthesis of an abnormal p53 protein, that may not only be inactive as a tumour suppressor, but can also bind and inactivate any non-mutated wild type p53, with an increase in oncogenic activity.[39] Although p53 mutations occur in HPV+OPC, they are far less common than in HPV-OPC (26% vs 48%), and do not appear to affect clinical outcome.[40]

The pRb protein is inactivated by E7 in HPV+OPC, but in HPV-OPC it is the p16 tumour suppressor part of the pRb tumour suppressor network that is inactivated. Also the pRb pathway is inactivated by E7 instead of Cyclin D1 amplification.[8][41] CDKN2A is a tumour suppressor gene that encodes a tumor suppressor protein, p16 (cyclin-dependent kinase inhibitor 2A) and inhibits the kinase activity of the cyclin-dependent kinases CDK4 and CDK6, which in turn induce cell cycle arrest.[38] p16 expression is cell cycle dependent and is expressed focally in only about 5–10% of normal squamous epithelium. Like most HPV+ cancers, HPV+OPC express p16 but the latter does not function as a tumour-suppressor, because the mechanism by which this is achieved, pRb, has been inactivated by E7. p16 is upregulated (over-expressed) due to E7-related loss of pRB with reduced negative feedback,[39][42] whereas it is downregulated in up to 90% of HPV-OPC.[43] This diffuse over-expression in the tumour cells provides a diagnostic marker for HPV involvement.[44][45] Although HPV E6 and E7 reduce tumour suppressor activity, they do so less than genetic and epigenetic processes do in HPV-OPC.[46][47][11]

The tonsillar epithelia (palatine and lingual) share similar nonkeratinization characteristics with the cervix, where HPV infection plays the major role in cases of cervical cancer.[14][48] Also E6 and E7 may make HPV+OPC more immunogenic than HPV-OPC, since anti-E6 and E7 antibodies may be detected in these patients. This in turn could restrict the malignant behaviour of HPV+OPC and the presence of antibodies has been associated with a better prognosis, while treatment may enhance the immunogenicity of the tumour, and hence improve response, although to what extent is not clear.[49][11] Outcomes are also associated with improved adaptive immunity.[50]

Diagnosis

Photo of rhinoscope used to visualise the oropharynx through the nose
Rhinoscope used in diagnosis and surveillance
CT Scan of right tonsil cancer
CT scan in transverse plane, viewed from below, showing a contrast enhancing right tonsil mass due to HPV+OPC

Biopsy

Initial diagnosis requires visualisation of the tumour either through the mouth or endoscopically through the nose using a rhinoscope, illustrated to the right, followed by biopsy.

Differentiating HPV+OPC from HPV-OPC

HPV+OPC is usually diagnosed at a more advanced stage than HPV-OPC,[8] with 75–90% having involvement of regional lymph nodes.[51] Furthermore, nonkeratinizing squamous cell carcinoma is strongly associated with HPV-OPC.[52][53]

Genetic signatures of HPV+ and HPV- OPC are different.[54][55][56][57][58] HPV+OPC is associated with expression level of the E6/E7 mRNAs and of p16.[59] HPV16 E6/E7-positive cases are histopathologically characterized by their verrucous or papillary (nipple like) structure and koilocytosis of the adjacent mucosa. Approximately 15% of HNSCCs are caused by HPV16 infection and the subsequent constitutive expression of E6 and E7, and some HPV-initiated tumors may lose their original characteristics during tumor progression.[60] High-risk HPV types may be associated with oral carcinoma, by cell-cycle control dysregulation, contributing to oral carcinogenesis and the overexpression of mdm2, p27 and cathepsin B.[61]

HPV+OPC is not merely characterized by the presence of HPV-16: only the expression of viral oncogenes within the tumor cells plus the serum presence of E6 or E7 antibodies is unambiguously conclusive for HPV+OPC.[14]

There is not a standard HPV testing method in head and neck cancers,[62] both in situ hybridization (ISH) and polymerase chain reaction (PCR) are commonly used.[44][63] Both methods have comparable performance for HPV detection, however it is important to use appropriate sensitivity controls.[64] Immunohistochemistry (IHC) staining of the tissue for p16 is frequently used as a cost-effective surrogate for HPV in OPC, compared to ISH or PCR[65][66][67] but there is a small incidence of HPV-negative p16-positive disease accounting for about 5% of HPV-OPC.[65]

Staging

Staging is generally by the UICC/AJCC TNM (Tumour, Nodes, Metastases) system.[67] Staging is based on clinical examination, diagnostic imaging, and pathology. On imaging, involved lymph nodes may appear cystic, a characteristic of HPV+OPC.[68]

HPV+OPC has been treated similarly to stage-matched and site-matched HPV unrelated OPC, but its unique features, which contrast smoking-related HPV-OPC head and neck cancers, for which patients' demographics, comorbidities, risk factors, and carcinogenesis differ markedly, suggest that a distinct staging system be developed to more appropriately represent the severity of the disease and its prognosis.[69] Standard AJCC TNM staging, such as the seventh edition (2009)[70] while predictive for HPV-OPC has no prognostic value in HPV+OPC.[71][72][66][69] The 8th edition of the AJCC TNM Staging Manual (2016)[73] incorporates this specific staging for HPV+OPC.[74] As of 2018, treatment guidelines are evolving to account for the different outcomes observed in HPV+OPC. Consequently, less intensive (de-intensification) use of radiotherapy or chemotherapy,[75] as well as specific therapy, is under investigation, enrolling HPV+OPC in clinical trials to preserve disease control and minimise morbidity in selected groups based on modified TNM staging and smoking status.[76][77][78][79][80]

HPV+ cancer of the oropharynx are staged as (AJCC 8th ed. 2016):[74] Tumour stage

  • T0 no primary identified
  • T1 2 cm or less in greatest dimension
  • T2 2–4 cm
  • T3 >4 cm, or extension to lingual surface of epiglottis
  • T4 moderately advanced local disease, invading larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible or beyond

Nodal stage

  • Nx regional lymph nodes cannot be assessed
  • N0 no regional lymph nodes involved
  • N1 one or more ipsilateral nodes involved, less than 6 cm
  • N2 contralateral or bilateral lymph nodes, less than 6 cm
  • N3 lymph node(s) larger than 6 cm

Clinical stage

  • Stage I: T0N1, T1–2N0–1
  • Stage II: T0N2, T1–3N2, T3N0–2
  • Stage III: T0–3N3, T4N0-3
  • Stage IV: any metastases (M1)

However, the published literature and ongoing clinical trials use the older seventh edition that does not distinguish between HPV+OPC and HPV-OPC - see Oropharyngeal Cancer - Stages.[81][82] The T stages are essentially similar between AJCC 7 and AJCC 8. with two exceptions. Tis (carcinoma in situ) has been eliminated and the division of T4 into substages (e.g. T4a) has been removed. The major changes are in the N stages, and hence the overall clinical stage. N0 remains the same, but as with the T stage, substages such as N2a have been eliminated. Extracapsular extension (ECE), also referred to as extranodal extension (ENE), which is invasion by the tumour beyond the capsule of the lymph node has been eliminated as a staging criterion.[lower-alpha 1]

This results in a HPV+OPC tumour being given a lower stage than if it were HPV-OPC. For instance, a 5 cm tumour with one ipsilateral node involved that is 5 cm in size but has ECE would be considered T3N3bM0 Stage IVB if HPV- but T3N1M0 Stage II if HPV+.[74]

Prevention

Vial of HPV vaccine

Avoiding exposure

Prevention of HPV+OPC involves avoiding or reducing exposure to risk factors where possible.

Vaccination

About 90% of HPV+OPC carry HPV 16, and another 5% type 18. These two types are both targets of available vaccines. HPV vaccines given prior to exposure can prevent persistent genital infection and the consequent precancerous state.[11] Therefore, they have a theoretical potential to prevent oral HPV infection.[8] A 2010 review study has found that HPV16 oral infection was rare (1.3%) among the 3,977 healthy subjects analyzed.[83]

Treatment

The goals of treatment are to optimise survival and locoregional disease control, and prevent spread to distant areas of the body (metastasis), while minimising short- and long-term morbidity.[84] There is no high quality Level I evidence from prospective clinical trials in HPV+OPC, therefore treatment guidelines must rely on data from treatment of OPC in general and from some retrospective unplanned subsetting of those studies, together with data for head and neck cancer in general.[67] Treatment for OPC has traditionally relied on radiotherapy, chemotherapy and/or other systemic treatments, and surgical resection. Depending on stage and other factors treatment may include a combination of modalities.[85] The mainstay has been radiotherapy in most cases.[66] a pooled analysis of published studies suggested comparable disease control between radiation and surgery, but higher complication rates for surgery +/- radiation.[85][86] Ideally a single modality approach is preferred, since triple modality is associated with much more toxicity, and a multidisciplinary team in a large centre with high patient volumes is recommended.[67][87][12]

Differences in response to treatment between HPV-OPC and HPV+OPC may include differences in the extent and manner in which cellular growth-regulatory pathways are altered in the two forms of OPC. For instance in HPV+OPC the HPV E6 and E7 oncogenes merely render the p53 and pRb pathways dormant, leaving open the possibility of reactivation of these pathways by down-regulating (reducing) expression of the oncogenes. This is in contrast to the mutant form of p53 found in HPV-OPC that is associated with treatment resistance.[11] Furthermore, it is suggested that the effects of E6 and E7 on these pathways renders the tumour more radiosensitive, possibly by interference with mechanisms such as DNA repair, repopulation signalling, and cell-cycle redistribution.[88][89] The microenvironment is also important, with radiation increasing host immune response to viral antigens expressed on the tumour.[50][49] Also, there is an association between an increase in tumour-infiltrating lymphocytes and in circulating white blood cells in HPV+OPC patients and better prognosis. This implies a role for an adaptive immune system in suppressing tumour progression.[90][91][89]

Surgery

Historically, surgery provided the single approach to head and neck cancer. Surgical management of OPC carried significant morbidity with a transcervical (through the neck) approach, often involving mandibulotomy, in which the jawbone (mandible) is split. This is referred to as an open surgical technique. Consequently, surgical approaches declined in favour of radiation. In the United States, the use of surgery declined from 41% of cases in 1998 to 30% by 2009, the year that the Food and Drug Administration approved the use of the newer techniques.[92]

These improvements in surgical techniques have allowed many tumours to be resected (removed) by transoral (through the mouth) surgical approaches (TOS), using transoral endoscopic head and neck surgery (HNS).[93] Consequently, surgery became used more, increasing to 35% of cases by 2012.[92] This approach has proven safety, efficacy and tolerability, and includes two main minimally invasive techniques, transoral robotic surgery (TORS)[94][95][96][97][98][99] and transoral laser microsurgery (TLM).[100][101][102] No direct comparisons of these two techniques have been conducted, and clinical trials in head and neck cancer such as ECOG 3311 allow either. They are associated with substantial postoperative morbidity, depending on extent of resection but compared to older techniques have shorter hospital stay, faster recovery, less pain, and less need for gastrostomy or tracheostomy, and less long-term effects, which are minimal in the absence of postoperative radiation (RT), or chemoradiation (CRT).[103][104] TORS has the practical advantage that angled telescopes and rotating robotic surgical arms provide better line of sight. Outcomes of minimally invasive procedures also compare favourably with more invasive ones. In early stage disease, including involvement of neck nodes, TORS produces a 2-year survival of 80–90%.[105] TLM similarly, is reported to have a five-year survival of 78% and local control rates of 85–97%.[106][107] In addition to early disease, minimally invasive surgery has been used in advanced cases, with up to 90% local control and disease specific survival.[94][107] Postoperative swallowing was excellent in 87%, but long-term dysphagia was associated with larger (T4) cancers, especially if involving the base of the tongue.[107] [12]

The details of the surgical approach depend on the location and size of the primary tumour and its N stage. Neck dissection to examine the draining lymph nodes may be carried out simultaneously or as a second staging procedure. For tumours of the tonsil and lateral pharyngeal wall, and clinically node negative (N0) disease, dissection of the neck typically involves levels 2–4 (see diagram in Dubner 2017) ipsilaterally. Where nodes are involved clinically, dissection will depend on the location and size of the node or nodes. In the case of tongue base primaries, close to the midline, bilateral dissection is recommended.[12]

Pathological staging

An advantage of a primary surgical approach is the amount of pathological information made available, including grade, margin status, and degree of involvement of lymph nodes. This may change the staging, as up to 40% of patients may have a different postoperative pathological stage compared to their preoperative clinical stage. In one study, 24% had their stage reduced (downstaged), which may impact subsequent decision making, including reduction in intensity and morbidity.[108][12] In the United Kingdom, the Royal College of Pathologists (1998)[109][lower-alpha 2] has standardised the reporting of surgical margins, with two categories, "mucosal" and "deep", and for each created groups based on the microscopic distance from invasive cancer to the margin, as follows: more than 5 mm (clear), 1–5 mm (close) and less than 1 mm (involved).[110]

Adjuvant postoperative therapy

Data on the use of postoperative radiation therapy (PORT) is largely confined to historical or retrospective studies rather than high quality randomized clinical trials and are based on the overall population of patients with head and neck cancer, rather than specific studies of HPV+OPC, which would have formed a very small proportion of the population studied.[12] Despite surgical excision, in the more advanced cases local and regional recurrence of the cancer, together with spread outside of the head and neck region (metastases) are frequent. The risk of subsequent recurrent disease has been considered highest in those tumours where the pathology shows tumour at the margins of the resection (positive margins), multiple involved regional lymph nodes and extension of the tumour outside of the capsule of the lymph node (extracapsular extension), based on historical experience with head and neck cancer.[111] PORT was introduced in the 1950s in an attempt to reduce treatment failure from surgery alone.[112] Although never tested in a controlled setting, PORT has been widely adopted for this purpose.[113] In an analysis of surgical treatment failure at Memorial Sloan-Kettering Cancer Center, patients treated with surgery alone between 1960–1970 had failure rates of 39 and 73% for those with negative and positive surgical margins respectively. These were compared to those who received PORT (with or without chemotherapy) from 1975–1980. The latter group had lower failure rates of 2% and 11% respectively.[114] In addition, one randomised study from the 1970s (RTOG 73-03) compared preoperative radiation to PORT, and found lower failure rates with the latter.[113][115]

The addition of another modality of treatment is referred to as adjuvant (literally helping) therapy, compared to its use as the initial (primary) therapy, also referred to as radical therapy. Consequently, many of these patients have been treated with adjuvant radiation, with or without chemotherapy. In the above series of reports of minimally invasive surgery, many (30–80%) patients received adjuvant radiation. However, functional outcomes were worse if radiation was added to surgery and worst if both radiation and chemotherapy were used.[12] Radiation dosage has largely followed that derived for all head and neck cancers, in this setting, based on risk. Historically only one randomised clinical trial has addressed optimal dosage, allocated patients to two dosage levels, stratified by risk, but showed no difference in cancer control between the low and high doses (63 and 68.4 Gy), but a higher incidence of complications at the higher doses. Consequently, the lower dose of 57.6 Gy was recommended.[116][117] Because the authors used a fractionation scheme of 1.8 Gy per treatment, this dosage was not widely adopted, practitioners preferring a larger fraction of 2 Gy to produce a shorter treatment time, and a slightly higher dose of 60 Gy in 2 Gy fractions (30 daily treatments).[41] Yet 57.6 Gy in 1.8 Gy fractions is equivalent (iso-effective dose) to only 56 Gy in 2 Gy fractions.[118] 60 Gy corresponds to the 63 Gy used as the low dose in the high risk group. 60 Gy was also the dose used in RTOG 73-03. Subsequently, there was a tendency to intensify treatment in head and neck cancer, and a number of centres adopted a dose of 66 Gy, at least for those patients with adverse tumour features.[119] The effectiveness of PORT in HPV+OPC receives some support from a cohort study (Level 2b), although the number of patients was low, and the number of events (recurrent disease or death) only 7%.[120] Another retrospective population-level study (Level 4) of the SEER database (1998–2011) concluded that there was an overall survival but not disease-specific survival effect of radiation in 410 patients with a single lymph node involved, but used only univariate statistical analysis and contained no information on HPV status.[121] A subsequent much larger study on a similar population in the National Cancer Database (2004–2013) of over 9,000 patients found a survival advantage but this was only in HPV-OPC, not in 410 HPV+OPC patients,[122] and a subsequent study of 2,500 low and intermediate risk HPV+OPC patients showed similar overall survival whether PORT was given or not.[123]

Deintensification

While less studies have been completed examining deintensification (de-escalation) in this setting, than in primary radical radiation for this cancer (see below), it is an area of active investigation.[124] In one single institution study, a decision was made to reduce the radiation dose in high risk patients with HPV+OPC from 66 to 60 Gy, corresponding to the actual evidence, and follow up has shown no decrease in cancer control.[119] Current trials, both in North America and Europe (such as ECOG 3311[lower-alpha 3] and PATHOS[lower-alpha 4]) use 50 Gy as the comparison arm.[126] The comparator of 50 Gy was chosen on the grounds of (i) the exquisite sensitivity of HPV+OPC to radiation, both in vitro and in vivo; ECOG 1308 showing excellent disease control at 54 Gy; and data[127] suggesting that 50 Gy in 1.43 Gy (iso-effective dose 43 Gy in 2.0 Gy) was sufficient to electively treat the neck.[125] Other studies, such as MC1273 and DART-HPV have evaluated doses as low as 30–36 Gy.[128] Lowering the radiation dose to 54 Gy was identified as one of the important Clinical Cancer Advances of 2018 by the American Society of Clinical Oncology, under the general theme of "Less Is More: Preserving Quality of Life With Less Treatment".[129] Chemotherapy has been used concurrently with radiation in this setting, as in primary treatment with radical radiation, particularly where pathological features indicated a higher risk of cancer recurrence. A number of studies have suggested that this does not improve local control, although adding toxicity.[130]

Radiotherapy

Diagram of radiation therapy contours used in treating a right tonsillar cancer
Transverse radiation contours used in treating cancer seen on above CT scan and in machine set up below
Person with HPV+OPC receiving IMRT PORT on Varian TruBeam linear accelerator with detail of restraining mask
Photograph of patient receiving radiation for oropharyngeal cancer
Detail of mask covering head and neck

Concerns over the morbidity associated with traditional open surgical en-bloc resection, led to exploring alternative approaches using radiation.[120] Intensity modulated radiation therapy (IMRT) can provide good control of primary tumours while preserving excellent control rates, with reduced toxicity to salivary and pharyngeal structures relative to earlier technology. HPV+OPC has shown increased sensitivity to radiation with more rapid regression, compared to HPV-OPC.[131] Generally, radiation can safely be delivered to the involved side alone (ipsilateral), due to the low rate of recurrent cancer on the opposite side (contralateral), and significantly less toxicity compared to bilateral treatment.[lower-alpha 5][133][132] IMRT has a two-year disease free survival between 82 and 90%, and a two-year disease specific survival up to 97% for stage I and II.[134][135]

Reported toxicities include dry mouth (xerostomia) from salivary gland damage, 18% (grade 2);[lower-alpha 6] difficulty swallowing (dysphagia) from damage to the constrictor muscles, larynx and oesophageal sphincter, 15% (grade 2); subclinical aspiration up to 50% (reported incidence of aspiration pneumonia approximately 14%); hypothyroidism 28–38% at three years (may be up to 55% depending on amount of the thyroid gland exposed to over 45 Gy radiation; esophageal stenosis 5%; osteonecrosis of the mandible 2.5%; and need for a gastrostomy tube to be placed at some point during or up to one year after treatment 4% (up to 16% with longer follow up).[12][137][135][138][139] Concerns have been expressed regarding excessive short- and long-term toxicity, especially dysphagia and xerostomia,[140][141][142] and hence whether standard doses expose patients with better prognoses are being exposed to overtreatment and unnecessary side effects.[143][89]

Dosimetry

The probability of xerostomia at one year increases by 5% for every 1Gy increase in dose to the parotid gland. Doses above 25–30 Gy are associated with moderate to severe xerostomia. Similar considerations apply to the submandibular gland, but xerostomia is less common if only one parotid gland is included in the radiated field[144] and the contralateral submandibular gland is spared (less than 39 Gy)[145] In the same manner, radiation dose to the pharyngeal constrictor muscles, larynx, and cricopharyngeal inlet determine the risk of dysphagia (and hence dependence on gastrostomy tube feeds). The threshold for this toxicity is volume-dependent at 55–60 Gy,[146][147][148][89] with moderate to severe impairment of swallowing, including aspiration, stricture and feeding tube dependence above a mean dose of 47 Gy, with a recommended dose to the inferior constrictor of less than 41 Gy.[149][150] Dose-toxicity relationships for the superior and middle constrictors are steep, with a 20% increase in the probability of dysphagia for each 10 Gy.[151] For late dysphagia, threshold mean total constrictor doses, to limit rates of greater than or equal to grade 2 and 3 below 5% were 58 and 61 Gy respectively. For grade 2 dysphagia, the rate increased by 3.4% per Gy.[152] Doses above 30 Gy to the thyroid are associated with moderate to severe hypothyroidism.[153] Subjective, patient-reported outcomes of quality of life also correlate with radiation dose received.[141]

Altered fractionation schemes, such as RTOG 9003 [lower-alpha 7][140] and RTOG 0129[lower-alpha 8] have not conferred additional benefit.[154][155] Radiation dose recommendations were largely determined empirically in clinical studies with few HPV+OPC patients, and have remained unchanged for half a century,[89] making it difficult to determine the optimum dose for this subgroup. A common approach uses 70 Gy bilaterally and anteriorly, such as RTOG 9003 (1991–1997)[140][154] and RTOG 0129 (2002–2005).[156][155] For lateralized tonsil cancer unilateral neck radiation is usually prescribed, but for tongue base primaries bilateral neck radiation is more common, but unilateral radiation may be used where tongue base lesions are lateralised.[12]

Deintensification

Concerns have been expressed regarding excessive short- and long-term toxicity, especially dysphagia and xerostomia,[140][141][142] and hence whether standard doses expose patients with better prognoses to overtreatment and unnecessary side effects.[143][89] Current toxicities have been described as "not tolerable",[157] and hence an intense interest in de-escalation.[126]

While comparison with historical controls has limited value compared to randomised clinical trials (phase III), phase II studies using reduced doses of radiation compared to the historical standard of 70 Gy have been carried out. A study using 54–60 Gy (a 15–20% reduction, stratified by response to initial induction chemotherapy) demonstrated comparable levels of disease control with much lower complication rates,[89] when compared to similar studies, using 70 Gy, such as ECOG 2399.[158][159] The percentage of patients alive after 2 years were 95% at the higher dose and 98% at the lower dose. Similarly for the percentage free of disease (86 and 92%). Toxicities were greatly reduced from an incidence of grade 3 or greater dysphagia and mucositis of 54 and 53% respectively, to 9%. A lower incidence and severity of dysphagia also means that less patients require gastrostomy feeding.[89] A similar comparison can be made with the pooled data from two RTOG studies which utilized 70 Gy (0129 and 0522).[160]

No new guidelines dealing specifically with HPV+OPC have yet been developed, outside of clinical trials. Indirect data suggests the efficacy of less intense treatment. A retrospective analysis of advanced (N+) HPV+OPC suggested 96% 5 year local control with de-intensified radiation of 54 Gy and concurrent cisplatin based chemotherapy.[161] The conclusions of the above pair of similar phase II trials have been supported by several other phase II trials. A prospective trial (ECOG 1308) demonstrated similar locoregional control with 54 Gy,[143] and another study, a high pathological complete response rate at 60 Gy.[162] The Quarterback trial[lower-alpha 9] showed comparable outcomes between 56 and 70 Gy.[163] and was followed by Quarterback 2, comparing 50 to 56 Gy.[lower-alpha 10] Similarly, the Optima trial showed good disease control with doses between 45 and 50 Gy.[164] Ongoing studies, following the experience of the Mayo Clinic trial (MC1273),[128] such as that the Memorial Sloan Kettering Cancer Center are exploring doses as low as 30Gy.[lower-alpha 11] These studies all used well below the previous standard dose of 70 Gy. Since long-term toxicity is associated with radiation dose, determining the efficacy of lower and hence less morbid doses of radiation is a priority, since many HPV+ patients can be expected to have long-term survival.[12]

Radiation is commonly utilised in combination with chemotherapy, but also may be used as a single modality, especially in earlier stages, e.g. T1-T2, N0-1, and its use in later stages is being explored in clinical trials such as RTOG 1333 which compares radiation alone to radiation with reduced chemotherapy, in non or light smokers.[12]

Chemotherapy

As with the radiotherapy data, most of the available knowledge on the efficacy of chemotherapy derives from the treatment of advanced head and neck cancer rather than specific studies of HPV+OPC. Since 1976, many clinical studies have compared CRT to RT alone in the primary management of locally advanced head and neck cancers and have demonstrated an advantage to CRT in both survival and locoregional control.[165][166] Cisplatin is considered the standard agent, and a survival advantage was seen for those patients who received radiation with concurrent cisplatin.[167] Despite this no trials directly comparing cisplatin with other agents in this context have been conducted. The other agent that is widely used is Cetuximab, a monoclonal antibody directed at the epidermal growth factor receptor (EGFR). A 10% survival advantage at three years was noted when cetuximab was given concurrently with radiation (bioradiation).[168] Cetuximab trials were completed prior to knowledge of HPV status.[169] Laboratory and clinical studies on the utility of cetuximab in this context are conflicting. The main toxicity is an acneiform rash, but it had not been compared directly to cisplatin in HPV+OPC, till RTOG 1016 (see Talk) addressed this question.[12][163] Analysis of the results three years after the trial was completed demonstrate that cetuximab is inferior to cisplatin.[170] Concurrent chemotherapy is also superior to chemotherapy alone (induction chemotherapy) followed by radiation.[165][12] Cetuximab shows no advantage when added to cisplatin in combination with radiation.[142] Although chemoradiation became a treatment standard based on clinical trials and in particular, meta-analyses, a subsequent population based study of patients with OPC, indicated no advantage to the addition of chemotherapy to radiation in either HPV+OPC or HPV-OPC,[171] and significant concerns about added toxicity.[172]

Chemotherapy also has a role, combined with radiation, in the postoperative setting (adjuvant therapy).[173] Generally it is used where the pathology of the resected specimen indicates features associated with high risk of locoregional recurrence (e.g. extracapsular extension through involved lymph nodes or very close margins). It has shown improved disease-free survival and locoregional control in two very similar clinical trials in such high risk patients, EORTC 22931 (1994–2000)[111] and RTOG 9501 (1995–2000).[lower-alpha 12][lower-alpha 13][lower-alpha 14][174][175][176] However, for HPV+OPC patients, such extracapsular spread does not appear to be an adverse factor[177][178][179] and the addition of chemotherapy to radiation in this group provided no further advantage.[178] Since the sample size to detect a survival advantage is large, given the small number of events in this group, these studies may have been underpowered and the question of the utility of adding chemotherapy is being addressed in a randomized clinical trial (ADEPT) with two year locoregional control and disease free survival as the endpoint.[lower-alpha 15] The addition of chemotherapy to radiation increases acute and late toxicity. In the GORTEC trial, chemotherapy with docetaxel provided improved survival and locoregional control in locally advanced OPC, but was associated with increased mucositis and need for feeding by gastrostomy.[180] Chemotherapy and radiation are associated with a risk of death of 3–4% in this context.[181] It is unclear whether the added toxicity of adding chemotherapy to radiation is offset by significant clinical benefit in disease control and survival.[12]

It is thought that HPV+OPC patients benefit better from radiotherapy and concurrent cetuximab treatment than HPV-OPC patients receiving the same treatment,[182] and that radiation and cisplatin induce an immune response against an antigenic tumour which enhances their effect on the cancer cells.[49] Although the incidence of HPV positivity is low (10–20%), an advantage for HPV+OPC was seen in trials of both cetuximab and panitumumab, a similar anti-EGFR agent, but not a consistent interaction with treatment, although HPV+OPC appears not to benefit to the same extent as HPV-OPC to second line anti-EGFR therapy, possibly due to lower EGFR expression in HPV+OPC.[169]

Choice of treatment approach

In the absence of high quality evidence comparing a primary surgical approach to other modalities, decisions are based on consideration of factors such as adequate surgical exposure and anatomically favourable features for adequate resection, post treatment function and quality of life. Such patient selection may enable them to avoid the morbidity of additional adjuvant treatment. In the absence of favourable surgical features the primary treatment of choice remains radiation with or without chemotherapy. Tumor characteristics which favour a non-surgical approach include invasion of the base of the tongue to the extent of requiring resection of 50% or more of the tongue, pterygoid muscle involvement, extension into the parapharyngeal fat abutting the carotid, involvement of the mandible or maxilla or invasion of the prevertebral space.[12]

The adequacy of surgical resection is a major factor in determining the role of postoperative adjuvant therapy. In the presence of a positive margin on pathological examination, most radiation oncologists recommend radiation to the primary site, and concurrent chemotherapy. A negative margin is more likely to be treated with lower doses and a smaller treatment volume. Also the removal of a bulky tumour may allow reduced dosage to adjacent uninvolved pharyngeal structures and hence less effect on normal swallowing.[75][12]

The cancer outcomes (local control, regional control, and survival) for transoral resection followed by adjuvant therapy are comparable to primary chemoradiation,[101][97][138] so that treatment decisions depend more on treatment-related morbidity, functional outcome, and quality of life. Patient factors also need to be taken into account, including general baseline functionality, smoking history, anesthesia risk, oropharyngeal function, swallowing and airway protection and potential for rehabilitation. Patient preference is equally important. Many clinical trials are under way focussing on deintensification, often with risk stratification, e.g. Low, Intermediate and High risk (see Fundakowski and Lango, Table I).[12][lower-alpha 16]

Clinical decisions also take into account morbidities, particularly if cancer outcomes are comparable for instance surgery is associated with a risk of bleeding between 5–10%, and a 0.3% risk of fatal postoperative haemorrhage.[102][183][98][99] Surgery may also be complicated by dysphagia, and while most patients can tolerate a diet on the first postoperative day, long-term use of a feeding tube has been reported as high as 10%.[107][98][99] Patients with larger tumours, involvement of base of tongue and requiring postoperative adjuvant therapy are more likely to require a long-term feeding tube.[184][185] Overall, function and quality of life appear relatively similar between surgery with postoperative radiation, and primary chemoradiation,[186][187][12] but HPV+OPC patients tend to have better quality of life at diagnosis than HPV-OPC but may sustain greater loss following treatment.[188]

Anatomical considerations may also dictate preference for surgical or non-surgical approaches. For instance trismus, a bulky tongue, limited extension of the neck, prominent teeth, torus mandibularis (a bony growth on the mandible) or limited width of the mandible would all be relative contraindications to surgery.[100] Tumour related considerations include invasion of the mandible, base of skull and extensive involvement of the larynx or more than half of the base of tongue.[101] Technical considerations in offering surgery as a primary modality include the presumed ability to achieve adequate margins in the resected specimen and the degree of resulting defect, since close or positive margins are likely to result in subsequent adjuvant therapy to achieve disease control, with resultant increased morbidity. Costs are difficult to estimate but one US study, based on estimates of 25% of all OPC patients receiving surgery alone and 75% surgery followed by adjuvant therapy, using the criteria of the NCCN, found that this approach was less expensive than primary chemoradiation.[189][190][191]

Early stage disease[lower-alpha 17] is associated with a relatively favourable outcome, for which single modality therapy is recommended, the choice depending on tumour location and accessibility. For instance unilateral tonsil or tongue base tumours will generally be treated with transoral resection and selective ipsilateral neck dissection. On the other hand, a large midline tongue lesion would require bilateral neck dissection, but in the absence of what are considered adverse pathology (positive margins, extracapsular extension) will likely be treated by surgery alone or radiation including ipsilateral or bilateral neck radiation fields, with surgery for those instances where the likelihood of adjuvant therapy is low.[12]

But many HPV+OPC present with involvement of the lymph nodes in the neck, and hence a higher stage of disease, generally referred to as locally advanced disease. This group is mostly treated with multimodality therapy, with the exception of one of the more favourable subgroups with small primary tumours and lymph node involvement confined to a single node no larger than 3 cm in size, which as noted are considered early stage disease. The three main options for locally advanced but operable disease are resection, neck dissection and adjuvant therapy; chemoradiation (with possible salvage surgery); induction chemotherapy followed by radiation or chemoradiation. However the last option has not been supported in clinical trials that tested it.[lower-alpha 18] The primary consideration of surgery for locally advanced disease is to obtain adequate negative margins and spare the patient postoperative chemoradiation. But this must be balanced against the morbidity and functional loss from extensive resection, particularly where the tongue base is involved. To avoid such morbidity, primary chemoradiation is preferred. The management of disease within the cervical lymph nodes has to be taken into account in treating locally advanced disease. Guidelines for all OPC dictate that ectracapsular extension be given postoperative chemoradiation. Where gross neck disease is evident initially primary chemoradiation is usually given.[12]

Patient preferences

Current guidelines are based on data for OPC as a whole, so that patients are generally being treated regardless of HPV status, yet many clinicians and researchers are considering deintensification.[194] It is likely that treatment of this condition will continue to evolve in the direction of deintensification, in order to minimize loss of function but maintain disease control.[195] In the absence of specific clinical trials and guidelines, patient preferences need to be taken into consideration to minimise short- and long-term toxicity and functional loss and optimize quality of life, given the prolonged survival frequently seen.[12] This may involve exploring patients' values regarding trade-offs of disease control against adverse effects of treatment. Patients who have received CRT as primary treatment for OPC place a high value on survival, and although agreeing that deintensification is desirable, were reluctant to trade off much survival advantage for lower toxicity, though would be more likely to forgo chemotherapy than accept reduced radiation.[196]

Carcinoma of unknown primary

In some situations HPV+OPC may present with cervical lymph nodes but no evident disease of a primary tumour (T0 N1-3) and is therefore classed as Squamous Cell Carcinoma of Unknown Primary Origin. The occurs in 2-4% of patients presenting with metastatic cancer in the cervical nodes. The incidence of HPV positivity is increasing at a similar rate to that seen in OPC. In such situations, resection of the lingual and palatine tonsils together with neck dissection may be diagnostic and constitute sufficient intervention, since recurrence rates are low.[197][198][199][200][201][12]

Prognosis

The presence of HPV within the tumour has been realised to be an important factor for predicting survival since the 1990s.[202]

Comparison with HPV-negative oropharyngeal cancer

Tumor HPV status is strongly associated with positive therapeutic response and survival compared with HPV-negative cancer, independent of the treatment modality chosen and even after adjustment for stage.[203] While HPV+OPC patients have a number of favourable demographic features compared to HPV-OPC patients, such differences account for only about ten per cent of the survival difference seen between the two groups.[11] Response rates of over 80% are reported in HPV+ cancer and three-year progression free survival has been reported as 75–82% and 45–57%, respectively, for HPV+ and HPV- cancer, and improving over increasing time.[12][204][205][206] It is likely that HPV+OPC is inherently less malignant than HPV-OPC, since patients treated by surgery alone have a better survival after adjustment for stage.[11]

Determinants of survival

In RTOG clinical trial 0129,[lower-alpha 19] in which all patients with advanced disease received radiation and chemotherapy, a retrospective analysis (recursive-partitioning analysis, or RPA) at three years identified three risk groups for survival (low, intermediate, and high) based on HPV status, smoking, T stage and N stage (see Ang et al., Fig. 2).[156] HPV status was the major determinant of survival, followed by smoking history and stage. 64% were HPV+ and all were in the low and intermediate risk group, with all non-smoking HPV+ patients in the low risk group. 82% of the HPV+ patients were alive at three years compared to 57% of the HPV- patients, a 58% reduction in the risk of death.[lower-alpha 20][156] Locoregional failure is also lower in HPV+, being 14% compared to 35% for HPV-.[159]

Determinants of disease progression

HPV positivity confers a 50–60% lower risk of disease progression and death, but the use of tobacco is an independently negative prognostic factor.[156][207] A pooled analysis of HPV+OPC and HPV-OPC patients with disease progression in RTOG trials 0129 and 0522 showed that although less HPV+OPC experienced disease progression (23 v. 40%), the median time to disease progression following treatment was similar (8 months). The majority (65%) of recurrences in both groups occurred within the first year after treatment and were locoregional. Although the rate of failure in the opposite neck following treatment of only one side, is 2.4%, the rate of an isolated recurrence in the opposite neck is 1.7%, and these were mainly where the primary tumour involved the midline. However the rate of failure in the contralateral neck is also greater for HPV+.[208] Of those that recur in this site, nearly all were successfully treated (salvaged) by further local treatment to the opposite neck.[132]

Determinants of metastasis rates

HPV+ did not reduce the rate of metastases (about 45% of patients experiencing progression), which are predominantly to the lungs (70%), although some studies have reported a lower rate.[209][160] with 3-year distant recurrence rates of about 10% for patients treated with primary radiation or chemoradiation.[210] Even if recurrence or metastases occur, HPV positivity still confers an advantage.[12][209][211] By contrast tobacco usage is an independently negative prognostic factor, with decreased response to therapy,[156][207] increased disease recurrence rates and decreased survival.[212] The negative effects of smoking, increases with amount smoked, particularly if greater than 10 pack-years.[156][207]

Predictors of survival

After chemoradiation

For patients such as those treated on RTOG 0129 with primary chemoradiation, detailed nomograms have been derived from that dataset combined with RTOG 0522, enabling prediction of outcome based on a large number of variables. For instance, a 71 year old married non-smoking high school graduate with a performance status (PS) of 0, and no weight loss or anaemia and a T3N1 HPV+OPC would expect to have a progression-free survival of 92% at 2 years and 88% at 5 years. A 60 year old unmarried nonsmoking high school graduate with a PS of 1, weight loss and anaemia and a T4N2 HPV+OPC would expect to have a survival of 70% at two years and 48% at five years.[213]

After surgery

Less detailed information is available for those treated primarily with surgery, for whom less patients are available,[120] as well as low rates of recurrence (7–10%), but features that have traditionally been useful in predicting prognosis in other head and neck cancers, appear to be less useful in HPV+OPC.[51] These patients are frequently stratified into three risk groups:[92]

  • Low risk: No adverse pathological features
  • Intermediate risk: T3–T4 primary, perineural or lymphovascular invasion, N2 (AJCC 7)[lower-alpha 1]
  • High risk: Positive margins, ECE

Development of other cancers

HPV+OPC patients are less likely to develop other cancers, compared to other head and neck cancer patients.[30] A possible explanation for the favourable impact of HPV+ is "the lower probability of occurrence of 11q13 gene amplification, which is considered to be a factor underlying faster and more frequent recurrence of the disease"[14] Presence of TP53 mutations, a marker for HPV- OPC, is associated with worse prognosis.[8] High grade of p16 staining is thought to be better than HPV PCR analysis in predicting radiotherapy response.[63]

Regional recurrence after surgery

The risk of regional cancer recurrence after neck dissection is often estimated[163] from a large series based on all upper aerodigestive squamous cell cancers. In this series, the overall risks at three years by pathological stage (AJCC 7) were:[214]

  • pN0 4.7%
  • pN1 4.9%
  • pN2 12.1%

Epidemiology

In 2015, squamous cell cancer of the head and neck region was the fifth most common cancer other than skin cancer, globally, with an annual incidence of 600,000 cases and about 60,000 cases annually in the United States and Europe.[215] The global incidence of pharyngeal cancer in 2013 was estimated at 136,000 cases.[12][216][217] For 2008 the Global Burden of Disease for OPC in 2008 is estimated at 85,000 cases, of which 22,000 were attributable to HPV, a population attributable fraction (PAF) of 26%. Of these, 17,000 were males and 4,400 females, 13,000 (60%) were aged between 50 and 69 years of age, and the majority of cases (15,000) were in developed regions compared to developing regions (6,400).[218][2] Age Standardised Incidence Rates (ASR) differ considerably by region and country (see de Martel et al., 2017 Fig. 2b).[218] ASRs for 2012 were highest in Europe (Hungary 3.0) and North America (United States 1.7) but much lower in Africa (≤ 0.3), Asia (≤ 0.6), Latin America (≤ 0.4) and Oceania (≤ 0.2) (other than Australasia, Australia 0.9).[219][218] Estimated average numbers of cases and ASR for the US in the period 2008–2012 were 15,738 and 4.5 respectively. HPV+OPC was much more common in males than females (12,638, 7.6 and 3,100, 1.7). The highest incidence age group was 60–69, and was higher in Caucasians than in other races.[220]

HPV+OPC patients tend to be younger than HPV- patients in general.[221] The clinical presentation is also changing from the “typical” head and neck cancer patient with advanced age and major substance usage.[12] By contrast patients with HPV+ cancer are younger (4th–6th decades), male (ratio 8:1) with no or only a minimum history of smoking, generally Caucasian, reached higher education levels, are married, and have higher income.[222] The risk factors for HPV-OPC and HPV+OPC tend to be independent, with the exception of smoking which has an adverse effect on both.[11] The presenting features are also different between HPV+ and HPV- OPC. HPV+ tumours have smaller primary lesions (less than 4 cm) but more advanced nodal disease resulting in higher TNM staging. This in turn may overestimate the severity of the disease status.[223][224]

There has been a global trend in increasing OPC incidence, particularly in North America and northern Europe, but even in Taiwan, which has a very high rate for all cancers of the head and neck region, OPC rates increased more rapidly between 1995 and 2009 than any other cancer site.[225][226] The Global Burden of HPV+OPC increased from 22,000 in 2008 to 29,000 by 2012, and the PAF from 26% to 31%,[218] and is considered an epidemic.[44] In the United States the estimated number of cases was 12,410 in 2008,[227] 13,930 in 2013[228] and 17,000 for 2017.[229] Of these cases, HPV+ cancer has been increasing compared to HPV- cancer, but the increase in HPV+OPC exceeds the decline in HPV-OPC resulting an overall increase in OPC.[11] The rise in pharyngeal cancer incidence contrasts with a marginal decline in other head and neck cancers.[230] As a result, the commonest head and neck cancer has shifted from larynx to oropharynx.[120] A survey of 23 countries between 1983 and 2002 showed an increase in oropharyngeal squamous cell carcinoma that was particularly noticeable in young men in economically developed countries.[217][12] In the United Kingdom the incidence of oral and oropharyngeal cancer in men rose 51%, from 7/100,000 to 11/100,000 between 1989 and 2006.[230] In the US there is a growing incidence of HPV associated oropharyngeal cancers,[231] In the early 1980s HPV+ accounted for only 7.5% of cases in the US but by 2016 this was 70%,[12][232][233][234] perhaps as a result of changing sexual behaviors, decreased popularity of tonsillectomies, improved radiologic and pathologic evaluation, and changes in classification.[235][236][237] Tonsil and oropharyngeal cancers increased in male predominance between 1975 and 2004, despite reductions in smoking.[238] HPV-OPC decreased with decreasing smoking rates from 1988 to 2004, while HPV+OPC increased by almost 7.5% per year from about 16% of all cases of OPC in the early 1980s to almost 70% in 2004.[222][239] The decline in smoking may be linked to the decreasing proportion of HPV negative cancers, while changes in sexual activity may be reflected in increasing proportion of HPV positive cancers.[222] Recently, in the US, HPV associated OPC represent about 60% of OPC cases[159][240] compared with 40% in the previous decade.[230] By 2007, in the US, incidence of general OPC, including non-HPV associated, is 3.2 cases per 100,000 males/year and 1.9 per 100,000 all-sexes/year.[241] This makes HPV+OPC one of only five cancers that have increased in incidence in the US since 1975.[242] The largest increase in incidence has occurred in patients under age 50.[243]

The increase in incidence of HPV associated OPC is also seen in other countries, like Sweden, with a 2007 incidence of over 80% for cancer in the tonsils,[244][245] Finland[246] and the Czech Republic.[247] Partners of patients with HPV positive oropharyngeal cancer do not seem to have elevated oral HPV infection compared with the general population.[248] In Australia the incidence of HPV associated OPC was 1.56 cases per 100,000 males/year (2001–2005), rising from 19% (1987–90), to 47% (2001–05) and 63.5% (2006–2010).[249][250] In Canada the percentage of cases of OPC attributable to HPV increased from 47% in 2000 to 74% in 2012.[251]

See also

  • HPV-associated oropharyngeal cancer awareness and prevention

Notes

  1. 1 2 N stage, AJCC 7th ed.[74]
    N1: one ipsilateral node involved, 3 cm or smaller, ECE negative (ECE-)
    N2a: one ipsilateral node 3–6 cm, ECE-
    N2b: more than one ipsilateral node, less than 6 cm, ECE-
    N2c: bilateral nodes, less than 6 cm, ECE-
    N3a: any lymph node larger than 6 cm, ECE-
    N3b: any lymph node ECE+
  2. ↑ Revised 3rd edition, 2013
  3. ↑ ECOG 3311 (NCT01706939) was activated in 2013 and completed accrual of 511 patients and is now in follow up - see Talk
  4. ↑ Planned accrual of 242 patients to PATHOS commenced in late 2014 - see Talk[125]
  5. ↑ Contralteral recurrence after unilateral treatment has been reported in only 2.4% of cases[132]
  6. ↑ Adverse effects are usually reported as grades 0–5, where 0 represents none and 5 represents death, corresponding to 1. mild, 2. moderate, 3. severe and 4. life-threatening. These are standardised as the Common Terminology Criteria for Adverse Events (CTCAE)[136]
  7. ↑ RTOG 9003 - see Talk
  8. ↑ RTOG0129 - see Talk
  9. ↑ NCT01706939 - see Talk
  10. ↑ NCT02945631 - see Talk
  11. ↑ NCT03323463 - see Talk
  12. ↑ RTOG 9501 randomized 459 patients with head and neck cancer and any or all of the following high risk features identified on the basis of previous trials: histologic evidence of invasion of two or more regional lymph nodes, extracapsular extension of nodal disease, and microscopically involved mucosal resection margins, between radiation and chemoradiation with cisplatin postoperatively. At five years, locoregional control was improved with chemotherapy but adverse events were greater. Distant metastases were not affected. Longer follow up to ten years showed that these differences were only seen in two high risk subgroups, those with positive margins and those with extracapsular extension
  13. ↑
    EORC 22931, also published in 2004, used a similar design but differing definition of high risk. It showed a similar early advantage for combined therapy
  14. ↑ RTOG 9501 - see Talk
  15. ↑ ADEPT - see Talk
  16. ↑ For instance ECOG 3311 stratifies HPV+OPC with AJCC 7 Stages III and IV 1-2, N1-2b into three risk groups postoperatively. Low risk is T1-T2 N0-N1 with negative margins. Intermediate risk is clear or close margins with the presence of adverse features on pathology such as perineural invasion or lymphovascular invasion, <1 mm ECE or 2–4 nodes involved. High risk is positive margins or greater than 1 mm ECE or at least 5 nodes involved.
  17. ↑ Early stage disease is considered as AJCC 7 as T1–22 N0–1 M0, approximately equivalent to T1–2 N0–2 M0 by AJCC 8
  18. ↑ Clinical trials, such as PARADIGM[192] and DeCIDE[193]
  19. ↑ RTOG 0129 - see Talk
  20. ↑ In RTOG 0129 the three prognostic groups were;
    • Low risk: HPV-, and had either less than 10 pack years of smoking, or more than 10 pack years but low nodal status (confined to a single node, >3 cm but ≤6 cm in greatest dimension)
    • Intermediate risk: HPV+ with >10 pack year smoking and more advanced nodal status, or HPV-, <10 pack years and tumour stage T2–T3
    • High risk: All others (including remainder of HPV-, <10 pack years with T4 tumours, and all with >10 pack years)

References

  1. ↑ de Martel et al 2012.
  2. 1 2 Forman et al 2012.
  3. ↑ Vokes et al 2015.
  4. ↑ Syrjänen et al 1983.
  5. 1 2 3 4 Mannarini et al 2009.
  6. ↑ IARC 1995.
  7. ↑ IARC 2007.
  8. 1 2 3 4 5 6 7 8 Chaturvedi & Gillison 2010.
  9. ↑ Gillison et al 2000.
  10. ↑ Westra 2009.
  11. 1 2 3 4 5 6 7 8 9 Lowy & Munger 2010.
  12. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 Fundakowski & Lango 2016.
  13. ↑ Ramqvist & Dalianis 2010.
  14. 1 2 3 4 5 Michl et al 2010.
  15. ↑ Vidal & Gillison 2008.
  16. ↑ Guan et al 2010.
  17. ↑ Frisch et al 1999.
  18. ↑ Anantharaman et al 2016.
  19. ↑ Haeggblom et al 2017.
  20. ↑ Underbrink et al 2008.
  21. ↑ Hemminki et al 2000.
  22. ↑ Tezal et al 2009.
  23. ↑ Tezal et al 2009a.
  24. ↑ Smith et al 2004.
  25. ↑ Schwartz et al 1998.
  26. ↑ D'Souza et al 2007.
  27. ↑ Heck et al 2010.
  28. 1 2 3 4 5 Chung et al 2016.
  29. ↑ Gillison 2006.
  30. 1 2 Martel et al 2017.
  31. ↑ Teach Me 2017.
  32. 1 2 Joshi et al 2013.
  33. ↑ McHanwell 2015.
  34. ↑ Lindberg 1972.
  35. 1 2 Ault 2006.
  36. 1 2 zur Hausen 2002.
  37. ↑ Smeets et al 2010.
  38. 1 2 Maslon & Hupp 2010.
  39. 1 2 Chung & Gillison 2009.
  40. ↑ Hong et al 2016a.
  41. 1 2 An et al 2016.
  42. ↑ Lawrence et al 2015.
  43. ↑ Ha & Califano 2006.
  44. 1 2 3 Marur et al 2010.
  45. ↑ Hunt 2010.
  46. ↑ Howard & Chung 2012.
  47. ↑ Licitra et al 2006.
  48. ↑ Salem 2010.
  49. 1 2 3 Spanos et al 2009.
  50. 1 2 Wansom et al 2010.
  51. 1 2 Sinha et al 2015.
  52. ↑ Chernock et al 2009.
  53. ↑ Elmofty & Patil 2006.
  54. ↑ Klussmann et al 2009.
  55. ↑ Lohavanichbutr et al 2009.
  56. ↑ Schlecht et al 2007.
  57. ↑ Weinberger et al 2009.
  58. ↑ Martinez et al 2007.
  59. ↑ Jung et al 2009.
  60. ↑ Yamakawa-Kakuta et al 2009.
  61. ↑ Cristina Mazon 2011.
  62. ↑ Robinson et al 2010.
  63. 1 2 Munck-Wikland, Hammarstedt & Dahlstrand 2010.
  64. ↑ Agoston et al 2010.
  65. 1 2 Seiwert 2014.
  66. 1 2 3 O'Sullivan et al 2016.
  67. 1 2 3 4 NCCN 2018.
  68. ↑ Goldenberg et al 2008.
  69. 1 2 Porceddu 2016.
  70. ↑ TNM 7 2010.
  71. ↑ Keane et al 2015.
  72. ↑ Huang et al 2015a.
  73. ↑ TNM 8 2017.
  74. 1 2 3 4 Lydiatt et al 2017.
  75. 1 2 Quon & Richmon 2012.
  76. ↑ Psyrri, Gouveris & Vermorken 2009.
  77. ↑ Lassen 2010.
  78. ↑ Fakhry & Gillison 2006.
  79. ↑ Brockstein & Vokes 2011.
  80. ↑ Givens et al 2009.
  81. ↑ NCI 2016.
  82. ↑ NCI 2016a.
  83. ↑ Kreimer et al 2010.
  84. ↑ Posner et al 2011.
  85. 1 2 Parsons et al 2002.
  86. ↑ Bourhis et al 2006.
  87. ↑ Corry et al 2015.
  88. ↑ Dok et al 2014.
  89. 1 2 3 4 5 6 7 8 Chen et al 2017.
  90. ↑ Huang et al 2015b.
  91. ↑ Ward et al 2014.
  92. 1 2 3 Routman et al 2017.
  93. ↑ Adelstein et al 2012.
  94. 1 2 Cohen et al 2011.
  95. ↑ Genden et al 2011.
  96. ↑ White et al 2010.
  97. 1 2 Rinaldi et al 2013.
  98. 1 2 3 Weinstein et al 2012.
  99. 1 2 3 Chia et al 2013.
  100. 1 2 Rich et al 2009.
  101. 1 2 3 Moore & Hinni 2013.
  102. 1 2 Canis et al 2012.
  103. ↑ Moore et al 2012.
  104. ↑ Choby et al 2015.
  105. ↑ Dowthwaite et al 2012.
  106. ↑ Steiner et al 2003.
  107. 1 2 3 4 Haughey et al 2011.
  108. ↑ Walvekar et al 2008.
  109. ↑ Helliwell & Woolgar 1998.
  110. ↑ Woolgar & Triantafyllou 2005.
  111. 1 2 Bernier et al 2004.
  112. ↑ Maccomb & Fletcher 1957.
  113. 1 2 Kramer et al 1987.
  114. ↑ Vikram et al 1984.
  115. ↑ Tupchong et al 1991.
  116. ↑ Peters et al 1993.
  117. ↑ Rosenthal et al 2017.
  118. ↑ ASTRO 2017.
  119. 1 2 Chin et al 2016.
  120. 1 2 3 4 Haughey & Sinha 2012.
  121. ↑ Monroe et al 2017.
  122. ↑ Olson & Clayburgh 2017, p. 99.
  123. ↑ Cramer et al 2018.
  124. ↑ Kelly et al 2016.
  125. 1 2 Owadally et al 2015.
  126. 1 2 Masterson et al 2014.
  127. ↑ Bedi et al 2012.
  128. 1 2 Ma et al 2017.
  129. ↑ Heymach et al 2018.
  130. ↑ Su et al 2016.
  131. ↑ Chen et al 2013.
  132. 1 2 3 Al-Mamgani et al 2017.
  133. ↑ O’Sullivan et al 2001.
  134. ↑ Maxwell et al 2014.
  135. 1 2 Hunter et al 2013.
  136. ↑ CTCAE 2010.
  137. ↑ Forastiere et al 2013.
  138. 1 2 de Almeida et al 2014.
  139. ↑ Al-Mamgani et al 2013.
  140. 1 2 3 4 Fu et al 2000.
  141. 1 2 3 Langendijk et al 2008.
  142. 1 2 3 Ang et al 2014.
  143. 1 2 3 Marur et al 2017.
  144. ↑ Deasy et al 2010.
  145. ↑ Robin et al 2016.
  146. ↑ Feng et al 2007.
  147. ↑ Li et al 2009.
  148. ↑ Caudell et al 2010.
  149. ↑ Eisbruch et al 2004.
  150. ↑ Vlacich et al 2014.
  151. ↑ Levendag et al 2007.
  152. ↑ Tsai et al 2017.
  153. ↑ Diaz et al 2010.
  154. 1 2 Beitler et al 2014.
  155. 1 2 Nguyen-Tan et al 2014.
  156. 1 2 3 4 5 6 Ang et al 2010.
  157. ↑ Bath 2017.
  158. ↑ Cmelak et al 2007.
  159. 1 2 3 Fakhry et al 2008.
  160. 1 2 Fakhry et al 2014.
  161. ↑ Woody et al 2016.
  162. ↑ Chera et al 2015.
  163. 1 2 3 Mirghani et al 2018.
  164. ↑ Seiwert et al 2018.
  165. 1 2 Blanchard et al 2011.
  166. ↑ Pignon et al 2007.
  167. ↑ Adelstein et al 2003.
  168. ↑ Bonner et al 2010.
  169. 1 2 Szturz et al 2017.
  170. ↑ NIH 2018.
  171. ↑ Hall et al 2017.
  172. ↑ Hall et al 2015.
  173. ↑ Bachaud et al 1996.
  174. ↑ Cooper et al 2004.
  175. ↑ Cooper et al 2012.
  176. ↑ Bernier et al 2005.
  177. ↑ Lewis et al 2011.
  178. 1 2 Sinha et al 2012.
  179. ↑ Maxwell et al 2013.
  180. ↑ Calais et al 2004.
  181. ↑ Machtay et al 2008.
  182. ↑ Erikson et al 2010.
  183. ↑ Pollei et al 2013.
  184. ↑ Sinclair et al 2011.
  185. ↑ Dziegielewski et al 2013.
  186. ↑ More et al 2013.
  187. ↑ Chen et al 2015.
  188. ↑ Sharma et al 2012.
  189. ↑ Moore et al 2009.
  190. ↑ Moore et al 2009a.
  191. ↑ Moore et al 2012a.
  192. ↑ Haddad et al 2013.
  193. ↑ Cohen et al 2014.
  194. ↑ Mehanna et al 2016.
  195. ↑ Mirghani et al 2015.
  196. ↑ Brotherston et al 2013.
  197. ↑ Durmus et al 2014.
  198. ↑ Graboyes et al 2015.
  199. ↑ Mehta et al 2013.
  200. ↑ Patel et al 2013.
  201. ↑ Galloway & Ridge 2015.
  202. ↑ Rischin et al 2010.
  203. ↑ Mehanna 2017.
  204. ↑ Dayyani et al 2010.
  205. ↑ de Jong et al 2010.
  206. ↑ Ragin & Taioli 2007.
  207. 1 2 3 Gillison et al 2012.
  208. ↑ Kato et al 2018.
  209. 1 2 Trosman et al 2015.
  210. ↑ O'Sullivan et al 2013.
  211. ↑ Sinha et al 2014.
  212. ↑ Maxwell et al 2010.
  213. ↑ Fakhry et al 2017.
  214. ↑ Ambrosch et al 2001.
  215. ↑ Siegel et al 2015.
  216. ↑ Myers & Sturgis 2013.
  217. 1 2 Chaturvedi et al 2013.
  218. 1 2 3 4 de Martel et al 2017.
  219. ↑ Johnson & Chaturvedi 2016.
  220. ↑ Viens et al 2016.
  221. ↑ Lajer et al 2010.
  222. 1 2 3 Chaturvedi et al 2011.
  223. ↑ Fischer et al 2010.
  224. ↑ Hafkamp et al 2008.
  225. ↑ Hwang et al 2015.
  226. ↑ Gillison et al 2015.
  227. ↑ Jemal et al 2008.
  228. ↑ Siegel et al 2013.
  229. ↑ Siegel et al 2017.
  230. 1 2 3 Mehanna et al 2010.
  231. ↑ Chenevert & Chiosea 2012.
  232. ↑ Sturgis & Cinciripini 2007.
  233. ↑ Ernster et al 2007.
  234. ↑ Hammarstedt et al 2006.
  235. ↑ Chenevert et al 2012.
  236. ↑ Chaturvedi et al 2008.
  237. ↑ Nguyen et al 2009.
  238. ↑ Cook et al 2009.
  239. ↑ Sturgis & Ang 2011.
  240. ↑ Adelstein & Rodriguez 2010.
  241. ↑ SEER 2010.
  242. ↑ Wirth 2016.
  243. ↑ Nguyen et al 2010.
  244. ↑ Nasman et al 2009.
  245. ↑ Hammarstedt 2008.
  246. ↑ Syrjänen 2004.
  247. ↑ Tachezy 2005.
  248. ↑ D'Souza et al 2014.
  249. ↑ Hong et al 2010.
  250. ↑ Hong et al 2016b.
  251. ↑ Habbous et al 2017.

Bibliography

  • "Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 Published: May 28, 2009 (v4.03)" (PDF). CTCAE. National Cancer Institute. 14 June 2010. Archived from the original (PDF) on 30 August 2017. Retrieved 3 August 2017.

Articles

Human Papilloma Virus (HPV) and molecular biology

Diagnosis and staging

  • Chenevert, J; Seethala, RR; Barnes, EL; Chiosea, SI (April 2012). "Squamous cell carcinoma metastatic to neck from an unknown primary: the potential impact of modern pathologic evaluation on perceived incidence of human papillomavirus-positive oropharyngeal carcinoma prior to 1970". The Laryngoscope. 122 (4): 793–796. doi:10.1002/lary.21899. PMID 22252715. S2CID 25749527.
  • Goldenberg, David; Begum, Shahnaz; Westra, William H.; Khan, Zubair; Sciubba, James; Pai, Sara I.; Califano, Joseph A.; Tufano, Ralph P.; Koch, Wayne M. (July 2008). "Cystic lymph node metastasis in patients with head and neck cancer: An HPV-associated phenomenon" (PDF). Head & Neck. 30 (7): 898–903. doi:10.1002/hed.20796. PMID 18383529. S2CID 32614424.
  • Huang, Shao Hui; Xu, Wei; Waldron, John; et al. (10 March 2015). "Refining American Joint Committee on Cancer/Union for International Cancer Control TNM Stage and Prognostic Groups for Human Papillomavirus–Related Oropharyngeal Carcinomas". Journal of Clinical Oncology. 33 (8): 836–845. doi:10.1200/JCO.2014.58.6412. PMID 25667292.
  • Keane, Florence K.; Chen, Yui-Hui; Neville, Bridget A.; Tishler, Roy B.; Schoenfeld, Jonathan D.; Catalano, Paul J.; Margalit, Danielle N. (1 August 2015). "Changing prognostic significance of tumor stage and nodal stage in patients with squamous cell carcinoma of the oropharynx in the human papillomavirus era". Cancer. 121 (15): 2594–2602. doi:10.1002/cncr.29402. PMID 25873094. S2CID 205670627.
  • Lydiatt, William M.; Patel, Snehal G.; O'Sullivan, Brian; Brandwein, Margaret S.; Ridge, John A.; Migliacci, Jocelyn C.; Loomis, Ashley M.; Shah, Jatin P. (March 2017). "Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual". CA: A Cancer Journal for Clinicians. 67 (2): 122–137. doi:10.3322/caac.21389. PMID 28128848.
  • O'Sullivan, Brian; Huang, Shao Hui; Su, Jie; et al. (April 2016). "Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study". The Lancet Oncology. 17 (4): 440–451. doi:10.1016/S1470-2045(15)00560-4. PMID 26936027.
  • Porceddu, Sandro V (April 2016). "A TNM classification for HPV+ oropharyngeal cancer". The Lancet Oncology (Editorial). 17 (4): 403–404. doi:10.1016/S1470-2045(15)00611-7. PMID 26936026.

Treatment

Surgery
Radiation
Chemotherapy and chemoradiation
Deintensification

Prognosis

Epidemiology

Books and conference proceedings

Chapters, monographs, reports and theses

Websites

Treatment guidelines

This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.